Alectinib: observed
16 studies: patients on it are followed, or it is given outside a trial. Page 1 of 1. Open to participants first (6), then studies with results posted, then the rest; newest registration first within each.
- Multi Omics Molecular Characteristics and Immunophenotyping of Lung Signet Ring Cell CarcinomaRecruitingNCT07207278Report a problem
- Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant TherapyRecruitingNCT06862869Report a problem
- The Patient-Reported Outcomes in ALK Positive Advanced NSCLC in ChinaNot yet recruitingNCT06586801Report a problem
- ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung CancerRecruitingNCT06532149Report a problem
- Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project)RecruitingNCT06234579Report a problem
- Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer PatientsEnrolling by invitationNCT04708639Report a problem
- A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.CompletedNCT05834348Results postedReport a problem
- Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.CompletedNCT04647110Results postedReport a problem
- Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment PatternsCompletedNCT04351334Results postedReport a problem
- Alectinib-induced Endocrine ToxicityCompletedNCT06339554Report a problem
- KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors IIActive, not recruitingNCT05525858Report a problem
- An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With AlectinibActive, not recruitingNCT04764188Report a problem
- PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort StudyStatus unknownNCT04115410Report a problem
- A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) InhibitorsCompletedNCT03546894Report a problem
- Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in KoreaCompletedNCT03271554Report a problem
- Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor TherapyNo longer availableNCT02271139Report a problem